Events - Pharvaris N.V.

Upcoming Events

Nov 30 - Dec 1, 2026

The British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference 2026

Dec 2, 2026 10:00 AM EST

9th Annual Evercore Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Dec 4 - Dec 6, 2026

The Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) 2026 Congress

Dec 9 - Dec 10, 2026

8th Global Urticaria Forum (GUF) 2026

Past Events

Nov 12 - Nov 14, 2026

53rd Brazilian Congress of Allergy and Immunology (ASBAI)

Supporting Materials

End of Progression of Hereditary Angioedema Attack Manifestations With Oral Deucrictibant Immediate-Release Capsule: Results From the Phase 3 RAPIDe-3 Trial 899.9 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial 813.6 KB

Nov 12 - Nov 16, 2026

2026 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

Supporting Materials

Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks: The Phase 3 CHAPTER-3 Trial 1 MB

Early and Sustained Effects of Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 223.1 KB

Economic Burden and Treatment Patterns Among Individuals With Hereditary Angioedema: a U.S. Closed Claims Analysis 320.8 KB

Oral Deucrictibant for Prophylaxis of Hereditary Angioedema Attacks: Final Results From the CHAPTER-1 Open-Label Extension 378.3 KB

Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant 772.4 KB

Evaluation of Safety Margins and Response to Deucrictibant Immediate-Release Capsule Combined With Deucrictibant Extended-Release Tablet 275.3 KB

Nov 9, 2026 1:30 PM EST

Guggenheim 3rd Annual Healthcare Innovation Conference

Click for Webcast

Nov 8 - Nov 11, 2026

ISPOR Europe 2026

Supporting Materials

Patient-Reported Outcomes in the Open-Label Extension of the CHAPTER-1 Study Assessing Long-Term Prophylactic Treatment with Oral Deucrictibant in Participants with Hereditary Angioedema 423.2 KB

Oct 28 - Oct 31, 2026

Spanish Society of Allergology and Clinical Immunology (SEAIC) 2026

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 769.1 KB

Oct 26 - Oct 29, 2026

AMCP Nexus 2026

Supporting Materials

On-demand treatment of hereditary angioedema attacks with oral deucrictibant immediate-release capsule: efficacy and safety results of the phase 3 RAPIDe-3 trial 224.2 KB

Long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema: final results of the phase 2 CHAPTER-1 open-label extension study 199.7 KB

Oct 23 - Oct 25, 2026

2026 HAEi Regional Conference Americas

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial (Poster) 662 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial (Presentation) 189 KB

End of Progression of Hereditary Angioedema Attack Manifestations with Oral Deucrictibant Immediate-Release Capsule: Results From the RAPIDe-3 Phase 3 Trial 361.4 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema 214.9 KB

Qualitative Insights From RAPIDe-3: Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 197.2 KB

Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Long-Term Safety and Efficacy Results From the Phase 2 CHAPTER-1 Open-Label Extension Study 1.2 MB

Oct 23 - Oct 25, 2026

The XXXVIII National Congress of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC)

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 409.3 KB

Results From the Phase 3 RAPIDe-3 Trial: Efficacy and Safety of Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks 454.8 KB

Oct 15 - Oct 18, 2026

JSA/WAO/APAPARI Joint Congress 2026

Supporting Materials

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: End of progression results from RAPIDe-3 221.8 KB

Oral deucrictibant immediate-release capsule for on-demand treatment of hereditary angioedema attacks: Results of the phase 3 RAPIDe-3 trial 273.4 KB

Oct 2 - Oct 4, 2026

Specialty Healthcare Consortium (SHC) Fall 2026 Conference

Supporting Materials

In Silico Modeling of Human, Rat, and Humanized Rat Bradykinin B2 Receptor-Deucrictibant Complexes 18.3 MB

End Of Progression of Attack Manifestations With Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks in the Phase 3 RAPIDe-3 Trial 352.3 KB

Pagination

Current page 1
Page 2
Page 3
…
Next page
Last page